Last reviewed · How we verify
ladostigil hemitartrate — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
ladostigil hemitartrate (ladostigil hemitartrate) — Avraham Pharmaceuticals Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ladostigil hemitartrate TARGET | ladostigil hemitartrate | Avraham Pharmaceuticals Ltd | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ladostigil hemitartrate CI watch — RSS
- ladostigil hemitartrate CI watch — Atom
- ladostigil hemitartrate CI watch — JSON
- ladostigil hemitartrate alone — RSS
Cite this brief
Drug Landscape (2026). ladostigil hemitartrate — Competitive Intelligence Brief. https://druglandscape.com/ci/ladostigil-hemitartrate. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab